Screener
Allogene Therapeutics ALLO Other Income (Expense)
Other Income (Expense) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest and other income, net | 3,573 | 5,516 |
| Interest expense | (300) | (150) |
| Other income (expenses), net | 212 | 92 |
| Total other income (expenses), net | 3,485 | 5,458 |
| Net loss | (42,607) | (59,733) |
| Other comprehensive income (loss): | ||
| Net unrealized gain (loss) on available-for-sale investments | (452) | 132 |
| Net comprehensive loss | $(43,059) | $(59,601) |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's other income (expense)?
- Allogene Therapeutics (ALLO) reported other income (expense) of $3.49M in Q1 2026.
- How has Allogene Therapeutics's other income (expense) changed year-over-year?
- Allogene Therapeutics's other income (expense) decreased by 36.1% year-over-year, from $5.46M to $3.49M.
- What is the long-term trend for Allogene Therapeutics's other income (expense)?
- Over 3 years (2021 to 2025), Allogene Therapeutics's other income (expense) has grown at a 114.9% compound annual growth rate (CAGR), from -$1.86M to $18.43M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Allogene Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude